What was the primary purpose of this 8-K filing for WellPoint, Inc.?

The primary purpose of this 8-K filing was to report the creation of direct financial obligations by WellPoint, Inc. specifically the issuance and sale of $1.5 billion in aggregate principal amount of its notes through a private placement.

How much capital did WellPoint, Inc. raise, and what will the funds be used for?

WellPoint, Inc. raised approximately $1.58 billion in net proceeds from the sale of the notes. While the filing does not explicitly state the intended use of proceeds, such capital raises typically support general corporate purposes, potential acquisitions, debt refinancing, or strategic investments.

What is the nature of the debt issued and its standing within the company's capital structure?

The company issued unsecured and unsubordinated notes. This means they rank equally with other unsecured and unsubordinated debt of WellPoint, Inc. However, they are effectively subordinated to any future secured debt and to all liabilities of WellPoint's subsidiaries, as the notes are not guaranteed by any subsidiary.

What are the key terms and risks associated with these notes for investors?

Key terms include specific interest rates and maturity dates for each note series. Investors should note the unsecured and effectively subordinated nature of the notes, meaning repayment depends on WellPoint's ability to meet its obligations and is subordinate to secured debt and subsidiary liabilities. The company also retains an option to redeem certain note series under specific conditions.

ELV 8-K: Financial Events

Summary

Elevance Health, Inc. (formerly WellPoint, Inc. at the time of filing) reported on December 15, 2004, a significant debt issuance through a private placement. The company successfully raised approximately $1.58 billion by selling various series of notes, including 3.750% Notes due 2007, 4.250% Notes due 2009, 5.000% Notes due 2014, and 5.950% Notes due 2034. These proceeds are expected to strengthen the company's financial position and provide flexibility for future operations or strategic initiatives. The issuance was conducted under Section 4(2) of the Securities Act of 1933 and Rule 144A for resale to qualified institutional buyers, indicating a focus on institutional investors. The notes are unsecured and unsubordinated obligations of WellPoint, Inc., meaning they rank equally with other unsecured debt but are effectively subordinated to any future secured debt and all liabilities of the company's subsidiaries. The filing also details the terms of the notes, including interest rates, payment schedules, maturity dates, and provisions for events of default and redemption, as well as the associated Registration Rights Agreement requiring the company to register the notes for resale within 90 days.

Key Highlights

1WellPoint, Inc. (now Elevance Health) raised approximately $1.58 billion in net proceeds from the sale of $1.5 billion aggregate principal amount of unsecured notes in a private placement.
2The notes were issued in four series with varying maturities (2007, 2009, 2014, 2034) and coupon rates (3.750%, 4.250%, 5.000%, 5.950%).
3The offering was conducted under Section 4(2) of the Securities Act and Rule 144A, targeting qualified institutional buyers and non-U.S. persons.
4The notes are unsecured and unsubordinated obligations of WellPoint, Inc., ranking pari passu with existing and future unsecured debt but junior to any future secured debt.
5The notes are effectively subordinated to all existing and future liabilities of WellPoint's subsidiaries, as they are not guaranteed by any subsidiary.
6The filing includes details on interest payment dates, maturity dates, and optional redemption provisions for certain note series.
7A Registration Rights Agreement mandates WellPoint to file a registration statement with the SEC within 90 days to allow for the resale of the notes.

Elevance Health, Inc. 8-K Report, Financial Obligation (Dec 15, 2004)

Summary

Key Highlights

Frequently Asked Questions